Home > Insider Trading > Filing (0001209191-19-045818)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1654151	Deciphera Pharmaceuticals Inc.	DCPH	Pharmaceutical Preparations (2834)	200299725

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1713712	Lee Daniel Flynn	C/O Deciphera Pharmaceuticals, Inc. 500 Totten Pond Road Waltham MA 02451	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-08-13	123,107	$1.89	147,607	No	4	M	Direct
Common Stock	Disposition	2019-08-13	93,395	$40.26	54,212	No	4	S	Direct
Common Stock	Disposition	2019-08-13	29,712	$41.33	24,500	No	4	S	Direct
Common Stock	Disposition	2019-08-13	25,000	$42.90	66,779	No	4	S	Indirect	By Daniel L. Flynn Irrevocable Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Indirect	By Daniel L. Flynn Irrevocable Trust

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2019-08-13	123,107	$0.00	123,107	$1.89

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
349,571		2025-12-17	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	55,270	Indirect	By Biochenomix, LLC

Footnotes

The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.995, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.805, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015.